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Abstract
The aims of our study were to analyse the risk factors for colonization by Extended-spectrum b-lactamases (ESBL)-producing Proteus
mirabilis (ESBL-PM) in rehabilitation patients and to characterize the molecular features of these strains. The study was conducted in two
rehabilitation centres located in Rome, Italy (Fondazione Santa Lucia IRCCS (FSL)), and Tel-Aviv, Israel (Tel-Aviv Sourasky Medical Center
(TASMC)). Carriage of ESBL-PM was surveyed by rectal swabs. Strain typing was performed by pulsed-ﬁeld gel electrophoresis (PFGE).
Identiﬁcation of ESBL genes was done by PCR and sequencing. Patients admitted to the same institutions without ESBL carriage were
included as controls. The study group included 70 and 41 patients from FSL and TASMC, respectively. In FSL, the multivariate analysis
identiﬁed severe acute brain injury (OR = 15, 95% CI = 3.2–69.5, p 0.001), decubitus ulcer (OR = 3.5, 95% CI = 1.2–9.8, p 0.018) and
recent treatment with quinolones (OR = 5.7, 95% CI = 1.07–30.1, p 0.042) as independent risk factors. ESBL-PM carriers stayed longer in
the hospital on average and were less likely to be discharged home. No signiﬁcant risk factor was identiﬁed in TASMC. There were no
similarities in PFGE types or ESBL genes between the ESBL-PM isolates from the two institutions. In both hospitals, a variety of PFGE types
existed but a single ESBL type predominated, namely TEM-92 in FSL (n = 64/70; 91%) and CTX-M-2 in TASMC (n = 37/41; 90%). A new
TEM ESBL variant, TEM-177 was identiﬁed in FSL. The clonal diversity and the predominance of a single ESBL type suggested that horizontal
gene transfer played an important role in dissemination of resistance. The development of a population analysis tool that would allow tracing
deeper genetic relationships is required.
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Abstract
Erroneous assignments of clinical isolates to the interpretative categories susceptible, intermediate and resistant can deprive a patient of
successful antimicrobial therapy. The rate of major errors (ME) and very major errors (vME) is dependent on: (i) the precision/standard
deviation (r) of the antibiotic susceptibility testing (AST) method, (ii) the diameter distributions, (iii) clinical breakpoints, and (iv) the width
of the intermediate zone. The European Committee on AST (EUCAST) has abandoned or decreased the intermediate zone for several
drug/species combinations. This study focused on the effects of discontinuing the intermediate category on the rate of interpretation errors.
In total, 10 341 non-duplicate clinical isolates were included in the study. For susceptibility testing the disc diffusion method was used. Error
probabilities were calculated separately for diameter values ﬂanking the interpretative category borders. Error probabilities were then
applied to the actual numbers of clinical isolates investigated and expected rates of ME and vME were calculated. Applying EUCAST AST
guidelines, signiﬁcant rates of ME/vME were demonstrated for all drug/species combinations without an intermediate range. Virtually all ME/
vME expected were eliminated in CLSI guidelines that retained an intermediate zone. If wild-type and resistant isolates are not clearly
separated in susceptibility distributions, the retaining of an intermediate zone will decrease the number of ME and vME. An intermediate
zone of 2–3 mm avoids almost all ME/vME for most species/drug combinations depending on diameter distributions. Laboratories should
know their epidemiology settings to be able to detect problems of individual species/drug/clinical breakpoint combinations and take
measures to improve precision of diameter measurements.
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Abstract
Bacteraemia due to carbapenemase-producing Enterobacteriaceae is an emerging medical problem. Management of this entity is
complicated by the difﬁculty in identifying resistance patterns and the limited therapeutic options. A cohort study was performed including
all episodes of bloodstream infection due to OXA-48-producing Enterobacteriaceae (O48PE), occurring between July 2010 and April 2012.
Data on predisposing factors, clinical presentation, therapy and outcome were collected from medical records. There were 40 cases of
bacteraemia caused by O48PE, 35 Klebsiella pneumoniae and ﬁve Escherichia coli. Patients were elderly with signiﬁcant comorbidities (57.5%
underlying malignancy). Thirty-ﬁve cases (87.5%) were nosocomial, and ﬁve (12.5%) were healthcare-associated. Patients had frequently
been exposed to antibiotics and to invasive procedures during hospitalization. The most common source of bacteraemia was the urinary
tract followed by deep intra-abdominal surgical site infection. Clinical presentation was severe sepsis or shock in 18 cases (45%). Extended-
spectrum b-lactamase production was detected in 92.5% of isolates. MIC90 for ertapenem, imipenem and meropenem were 32, 16 and
16 mg/L, respectively. Most frequently preserved antibiotics were amikacin, colistin, tigecycline and fosfomycin. These antibiotics combined
are the basis of targeted therapies, including carbapenem in selected cases. Median delay in starting clinically adequate and microbiologically
appropriate treatment was 3 days. Crude mortality during admission and within 30 days from bacteraemia was 65% and 50%, respectively.
Bloodstream infections caused by O48PE have a poor prognosis. Delay in diagnosis and in initiation of optimal antimicrobial therapy is
frequent. Suspicion and rapid identiﬁcation could contribute to improving outcomes.
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Abstract
No detailed data exist in the literature on the accurate diagnosis of chronic brucellar meningitis or meningoencephalitis. A multicentre
retrospective chart review was performed at 19 health centres to determine sensitivities of the diagnostic tests. This study included 177
patients. The mean values of CSF biochemical test results were as follows: CSF protein, 330.64  493.28 mg/dL; CSF/ blood-glucose ratio,
0.35  0.16; CSF sodium, 140.61  8.14 mMt; CSF leucocyte count, 215.99  306.87. The sensitivities of the tests were as follows: serum
standard tube agglutination (STA), 94%; cerebrospinal ﬂuid (CSF) STA, 78%; serum Rose Bengal test (RBT), 96%; CSF RBT, 71%; automated
blood culture, 37%; automated CSF culture, 25%; conventional CSF culture, 9%. The clinician should use every possible means to diagnose
chronic neurobrucellosis. The high seropositivitiy in brucellar blood tests must facilitate the use of blood serology. Although STA should be
preferred over RBT in CSF in probable neurobrucellosis other than the acute form of the disease, RBT is not as weak as expected.
Moreover, automated culture systems should be applied when CSF culture is needed.
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